FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
- Laura Fiammenghi†1,
- Valentina Ancarani†1,
- Tilman Rosales2,
- Jay R Knutson2,
- Massimiliano Petrini1,
- Anna Maria Granato1,
- Elena Pancisi1,
- Laura Ridolfi1,
- Ruggero Ridolfi1,
- Angela Riccobon1 and
- Paolo Neyroz3Email author
© Fiammenghi et al; licensee BioMed Central Ltd. 2010
Received: 14 December 2009
Accepted: 3 June 2010
Published: 3 June 2010
Antigen processing by dendritic cells (DC) exposed to specific stimuli has been well characterized in biological studies. Nonetheless, the question of whether autologous whole tumor lysates (as used in clinical trials) are similarly processed by these cells has not yet been resolved.
In this study, we examined the transfer of peptides from whole tumor lysates to major histocompatibility complex class II molecules (MHC II) in mature dendritic cells (mDC) from a patient with advanced melanoma. Tumor antigenic peptides-MHC II proximity was revealed by Förster Resonance Energy Transfer (FRET) measurements, which effectively extends the application of fluorescence microscopy to the molecular level (<100Å). Tumor lysates were labelled with Alexa-488, as the donor, and mDC MHC II HLA-DR molecules were labelled with Alexa-546-conjugated IgG, as the acceptor.
We detected significant energy transfer between donor and acceptor-labelled antibodies against HLA-DR at the membrane surface of mDC. FRET data indicated that fluorescent peptide-loaded MHC II molecules start to accumulate on mDC membranes at 16 hr from the maturation stimulus, steeply increasing at 22 hr with sustained higher FRET detected up to 46 hr.
The results obtained imply that the patient mDC correctly processed the tumor specific antigens and their display on the mDC surface may be effective for several days. These observations support the rationale for immunogenic efficacy of autologous tumor lysates.
Dendritic cells (DC) are the most potent leukocyte populations which control the primary immune response . As antigen-presenting competent cells, they recognize and process antigens in the peripheral blood and tissues, migrate to draining lymph nodes, and finally present antigens to the target resting lymphocytes. Antigens are very efficiently internalized and processed by immature DC (iDC), but to achieve a productive T-cell response iDC must differentiate to mature DC (mDC), which express high levels of the cell-surface antigen-bearing major histocompatibility complex, class II (MHC II). In the multifaceted set of relationships that exist between the immune system and cancer, therapeutic vaccination has been accepted as a valid approach to overcoming the established state of immunotolerance between the two systems [2, 3]. The use of DC, derived from peripheral blood precursors and pulsed with tumor antigens, forms the basis of experimental and clinical trials on anti-tumor vaccinations [4, 5]. Although overall response rates for vaccination are still somewhat limited, results obtained with DC vaccinations can be considered a very promising therapeutic strategy . To refine the implementation of this approach, evaluation of both the DC migration activity to lymphatic tissues, and the correct presentation of tumor antigens in MHC II complexes at the DC membrane surface, is of critical importance. From this perspective, translational work to link the results from studies at the cellular and molecular level with those from clinical investigations is of great interest.
In a previous report, in vivo DC migration was investigated within the context of a clinical trial of anti-tumor vaccination . In particular, it was shown that mDC exhibit a six- to eightfold higher migration rate than iDC. Following that study, here we have investigated the molecular traits of the MHC II complexes of DC from a melanoma patient pulsed with autologous whole tumor lysate (ATL).
Our aim was to show that the autologous lysate (diverse, in character or content of tumor specific antigens, from isolated peptides, but representing the real "drug") could be processed by the patient's DC and loaded on the membrane surface as MHCII complexes, a crucial information for the clinical evaluation of patients involved in vaccination therapy trials.
Dendritic cells (DC) were prepared as described previously . Peripheral blood monocytes obtained by leukapheresis without previous mobilization were purified on Ficoll-Paque gradients (Ge Healthcare Milan, Italy), incubated in tissue culture flasks with CellGro DC medium (Cell Genix, Freiburg, Germany) at a density of 107 cells/ml for 2 hr, and the adherent cells were incubated in CellGro DC medium containing 1000 IU/ml rhIL-4 and 1000 IU/ml rhGM-CSF (Cell Genix, Freiburg, Germany) for 7 days. On day 6, the DC culture was pulsed with autologous tumor lysate (ATL) (100 μg/ml). On day 7, the cells were defined as immature DC (iDC). After eliminating the previous culture medium, pulsed iDC were cultured for a further 2 days with a cocktail of cytokines (TNFα, IL-1β, IL-6, Cell Genix, Freiburg, Germany; Prostin E2, Pfizer, Puurs, Belgium). On day 9, the cells were defined as mature DC (mDC). iDC and mDC phenotypes were determined by single or two-color fluorescence analysis.
ATL preparation and labeling
Surgically removed tumor samples were mechanically and enzymatically dispersed to create a single-cell suspension in RPMI 1640 (PAA Laboratories GmbH, Pasching, Austria) and the tumor lysate was prepared as described previously . Protein concentrations were determined and aliquots were stored at -80°C until use. For fluorescence labeling, ATL was reacted with Alexa Fluor®-488 succinimidyl ester (Molecular Probes-Invitrogen, USA) according to the supplier's instructions. Size-exclusion chromatography on Sephadex G-25 superfine (Ge Healthcare Milan, Italy) was used to separate the bound from the free dye. Analytical sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) on gradient (4%-20%) was performed to evaluate the protein content of ATL and the goodness of the fluorescence labeling.
Cells (3 × 105), pulsed with ATL-Alexa488 (80 μg/106 DC), were plated on coverslips pretreated with poly-D-lysine (Sigma Milan, Italy) and fixed with several drops of cold methanol at -20°C for 2 min. Cells were stained with mouse monoclonal HLA-DR (HL12) primary antibody (Santa Cruz, CA, USA) (1:100), followed by Alexa Fluor®-546 goat anti-mouse IgG (Molecular probes, Invitrogen) (1:2000).
Confocal FRET measurements
where D postbleach is the fluorescence intensity of the donor after photobleaching and D prebleach is the fluorescence intensity of the donor before photobleaching. As a control, non-bleached areas were also analyzed for FRET. Before- and after-photobleaching, images were acquired by simultaneous excitation with 488 nm and 561 nm laser lines at 5% and 9% of the total power intensity, respectively. Photobleaching was obtained by scanning in a zoomed region, over six vertical Z sections, with the 561 nm excitation laser line at 100% of its power intensity.
In FRET experiments a donor and an acceptor are defined by the overlap between the emission spectrum of the first and the excitation spectrum of the second. An excited donor will return to the ground state through an acceptor via FRET provided that the acceptor molecule is in close vicinity (<~80Å). In our experimental design, Alexa488-ATL molecules represent the donor and Alexa546-(AbII-AbI)-HLA-DR represent the acceptor. Under these conditions, detection of FRET is an accurate signature of proximity (requiring physical interaction) between ATL peptides and HLA-DR molecules. The efficiency of FRET is strongly distance dependent, so overall FRET efficiencies will have an upper limit set by the distance of closest approach between the ATL dye and the dye on the secondary antibody.
mDC FRET efficiency measured 16 hr and 46 hr after maturation stimulus
mDC 16 hr
mDC 46 hr
FRET efficiency analysis
It should be noted that in extremely (donor or acceptor) overloaded cells, FRET might sometimes be detected as a result of accidental proximity due to surface density-dependent interactions [12–14]. To be certain our FRET results heralded true proximity, we tested FRET levels versus loading on a pixel by pixel basis. Any "artifactual" FRET from overloading should be strongly correlated with levels per pixel. Under our experimental conditions, the total tumor lysate fluorescence (donor), complexed at the mDC membrane surface, should be intrinsically depleted due to the intracellular antigen degradation and processing events. For this reason, we assumed that only the MHC II molecules (acceptor) could represent a source of artifactual FRET.
Figure 2B shows a plot of the acceptor levels versus FRET efficiency. This analysis strongly indicates that E% is independent of acceptor levels, and thus negates interpretations that sever the link between FRET efficiency and tumor lysate peptide-MHC II proximity.
Proof of the specific activation of immune responses is crucial in the overall rationale of cancer immunotherapy, and, more specifically, it is needed to convincingly address any analysis of immunogenic efficacy. In the present work we evaluated the presentation of ATL peptides onto MHC II of mDC from a patient with advanced melanoma.
The pattern of the protein content of ATL has been presented in Figure 1B together with the result of its homogeneous fluorescence labeling. These products were used previously to monitor the uptake and the processing of ATL in DC by fluorescence microscopy imaging . Here, the antigens (ATL) and antigen-capturing molecules (MHC II) were tagged to act as donor-acceptor pairs, and FRET measurements were performed to resolve the physical interactions between ATL and MHC II. Under these conditions, our results indicate a significant correlation between FRET efficiency and the time after maturation stimulus (Figure 2A). This observation is consistent with an increasing transfer of ATL peptide-loaded MHC II molecules on the mDC membrane. This process is significant 22 hr after maturation, and antigen presentation remains fully effective after 46 hr. The kinetic response observed is in excellent agreement with those reported on the transport of specific HEL-peptide-MHC II complexes at the DC surface , and the accumulation of MHC II complexes on mDC induced by inflammatory stimuli . Yet, in accord with these reports, the apparent discrepancy between the high levels of acceptor fluorescence and the absence of FRET detection shortly after maturation (≤4 hours), could possibly be related to the rapid turnover of unloaded MHC II molecules observed in developing DCs.
In Figure 2B we addressed the potential effects of MHC II density over FRET by plotting acceptor levels versus the efficiency, E%. This test was developed to study the distribution of proteins at the apical surface of MDCK cells . In particular, in the appendix of that survey, the theoretical dependence of FRET was separated into random or clustered distribution of donor- and acceptor-labeled molecules. It was clearly shown that the clustered model predicts that the efficiency will be independent of the surface densities of the labeled molecules. As mentioned above, given that newly synthesized class II molecules are produced in increased amounts in the first 24 hours after maturation , in our study we were particularly cautious about the FRET detection bias due to acceptor overcrowding . In this respect, a more distinctive feature of MHC II organization on the plasma membrane of DC was elucidated recently by Unternaehrer and coworkers  in which MHC II molecules were found to cluster by a lateral association mediated mechanism.
In our study, the independence of E% from acceptor levels (random distribution of E%) clearly indicates the absence of a nonspecific density contribution to FRET and fits the clustered model. Thus, we assign the significant increase of FRET efficiency, observed at the membrane surface as a function of time from maturation, to the actual transfer of specific tumor antigen peptides into MHC II clustered complexes.
This single-case survey on an advanced melanoma vaccination trial shows that autologous tumor lysates are correctly processed and presented at the mDC membrane surface in melanoma patients. In addition, this time-dependent profile is consistent with a delayed mDC antigen display, a property that is crucial for their role in vaccination-triggered immune surveillance . Yet, the methodology described and the parameters obtained (i.e. FRET signals) can be applied to follow-up studies to analyze and evaluate their prognosis value in addressing the efficacy of immunotherapy protocols.
Finally, it is worth commenting on the potential wealth of information that could be gleaned from FRET measurements when maximal FRET efficiency is known. In favorable circumstances, a quantitative data analysis approach is possible (i.e. a measure of the absolute changes in the amounts of antigen-loaded MHC II molecules at the DC membrane surface). Unfortunately, this information can only be obtained from extensive studies where appropriate standards are available (i.e. oligonucleic acid hybrids, streptavidin-biotin coupled donor-acceptor pairs) , or when specific tagged molecules can be engineered . Under our particular experimental conditions, we could not define the maximal FRET efficiency of the investigated donor-acceptor system (Alexa488-ATL - Alexa546-(AbII-AbI)-HLA-DR). Additional "semi-quantitative" data interpretation would be affected by large approximations, and would also rely on uncertain assumptions. Nonetheless, the measured relative changes of FRET efficiency with time from maturation are intrinsically significant and relevant for the clinical evaluation of immunotherapy vaccination trials.
It has to be pointed out that we chose the acceptor photobleaching FRET method for its complete insensitivity to certain artifacts, including the direct excitation of acceptor. According to this FRET measurement method, both of the images (i.e. the green and in the red channels) were acquired before and after photobleaching through the appropriate emission barrier filters. Moreover, for each sample, three different staining preparations were carried out: +Alexa488 -Alexa546; +Alexa488 +Alexa546; -Alexa488 +Alexa546. All the sample preparations were analyzed before the active photobleaching FRET measurements. Under our experimental conditions, no significant background of Alexa 546 excitation in the absence of Alexa488 was observed. Furthermore, the test presented in Figure 2B (acceptor levels vs. E%) was weighted against the presence of crosstalk artifacts.
Using confocal microscopy FRET  we have been able to detect the transfer of specific peptides into MHC II complexes at the membrane surface of mDC. Moreover, the profile of the appearance of MHC II - tumor lysate antigen complexes, as a function of time after the maturation stimulus, is in good agreement with the results from previous biological studies on mouse  and human DC . In conclusion, our findings suggest that, in cancer vaccination immunotherapy procedures: i) autologous tumor lysates are correctly processed by DC in vitro and ii) the resulting antigenic peptides are properly loaded on mDCs' MHC II complexes. This study reinforces the rationale behind the immunogenic efficacy of cancer vaccination treatments.
Autologous Tumor Lysate
Energy Transfer Efficiency
Förster Resonance Energy Transfer
human leukocyte antigen DR
major histocompatibility complex class II
Region of interest. SDS-PAGE: sodium dodecyl sulphate polyacrylamide gel electrophoresis.
The authors wish to thank Dr. Sundararajan Venkatesan and Dr. Ling Yi from the National Institute of Allergy and Infectious Diseases (NIH, Bethesda, USA) for helpful discussion and assistance in running the Leica SP5 TCS confocal apparatus. This project was supported by the Research Program of the Polo Scientifico - Didattico di Rimini, RFO 2007 at the University of Bologna, and was partially funded by Compagnia di San Paolo, Torino. The authors also wish to thank Dr. Ian Seymour for editing the manuscript.
- Hart DN: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997, 90: 3245-3287.PubMed
- Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001, 61: 6451-6458.PubMed
- Ichim CV: Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med. 2005, 3: 8-10.1186/1479-5876-3-8.PubMedPubMed CentralView Article
- O'Neill DW, Adams S, Bhardwaj N: Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004, 104: 2235-2246. 10.1182/blood-2003-12-4392.PubMedView Article
- Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005, 5: 296-306. 10.1038/nri1592.PubMedView Article
- Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M, Migliori G, Riccobon A: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med. 2006, 4: 36-10.1186/1479-5876-4-36.PubMedPubMed CentralView Article
- Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Moretti A, Migliori G, Fiorentini G: Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med. 2004, 2: 27-10.1186/1479-5876-2-27.PubMedPubMed CentralView Article
- Bastiaens PIH, Jovin TM: Fluorescence resonance energy transfer (FRET) microscopy. Cell biology: a laboratory handbook. Edited by: Celis JE. 1998, New York, Academic Press, 136-146. 3
- Turley SJ, Inaba K, Garrett WS, Ebersold M, Unternaehrer J, Steinman RM, Mellman I: Transport of peptide-MHC class II complexes in developing dendritic cells. Science. 2000, 288: 522-527. 10.1126/science.288.5465.522.PubMedView Article
- Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature. 1997, 388: 782-787. 10.1038/42030.PubMedView Article
- Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, Germain RN, Mellman I, Steinman RM: The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med. 2000, 191: 927-936. 10.1084/jem.191.6.927.PubMedPubMed CentralView Article
- Vogel SS, Thaler C, Koushik SV: Fanciful FRET. Sci STKE. 2006, 2006: re2-10.1126/stke.3312006re2.PubMed
- Wallrabe H, Elangovan M, Burchard A, Periasamy A, Barroso M: Confocal FRET microscopy to measure clustering of ligand-receptor complexes in endocytic membranes. Biophys J. 2003, 85: 559-571. 10.1016/S0006-3495(03)74500-7.PubMedPubMed CentralView Article
- Kenworthy AK, Edidin M: Distribution of a glycosylphosphatidylinositol-anchored protein at the apical surface of MDCK cells examined at a resolution of <100 A using imaging fluorescence resonance energy transfer. J Cell Biol. 1998, 142: 69-84. 10.1083/jcb.142.1.69.PubMedPubMed CentralView Article
- Ancarani V, Fiammenghi L, Petrini M, Pancisi E, Ridolfi L, Ridolfi R, Riccobon A, Neyroz P: Fluorescence microscopy imaging to monitor dendritic cell's tumor lysate capturing and processing: preliminary data [abstract]. Italian J Biochem, Special Issue. 2007, 129:
- Unternaehrer JJ, Chow A, Pypaert M, Inaba K, Mellman I: The tetraspanin CD9 mediates lateral association of MHC class II molecules on the dendritic cell surface. Proc Natl Acad Sci USA. 2007, 104: 234-239. 10.1073/pnas.0609665104.PubMedPubMed CentralView Article
- Gilboa E: DC-based cancer vaccines. J Clin Invest. 2007, 117: 1195-1203. 10.1172/JCI31205.PubMedPubMed CentralView Article
- Lim TC, Bailey VJ, Ho Y-P, Wang T-H: Intercalating dye as an acceptor in quantum-dot-mediated FRET. Nanotechnology. 2008, 19: 075701-10.1088/0957-4484/19/7/075701. (7pp) doi: 10.1088/0957-4484/19/7/075701PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.